Opdivo (nivolumab) significantly prolongs the time patients with resected esophageal or gastroesophageal junction (GEJ) cancer live without signs of disease after receiving chemoradiation therapy followed by cancer removal surgery, interim data from a Phase 3 trial show. Consistent with data from previous studies, Opdivo demonstrated a favorable safety profile in this setting. This is the second cancer, after melanoma, in which Opdivo demonstrated benefits as an adjuvant therapy — a treatment given after surgery to prevent…
You must be logged in to read/download the full post.
The post Post-surgery Opdivo Shows Benefits for Esophageal, GEJ Cancer Patients in Ongoing Trial appeared first on BioNewsFeeds.